ALLG

Improving the treatment and the lives of patients with blood cancers through clinical trial research

AUSTRALASIAN LEUKAEMIA AND LYMPHOMA GROUP

Trials Newsletter No 6

February 2015

This newsletter is published approximately every two months and provides update information on the ALLG trial program. Other ALLG activities are covered in the general newsletter published three times a year. To see the latest issue click HERE.

ALLG Trial Centre

Fax (Trial Registration, SAEs): +61(0)3 9429 8277

Note new address: 35 Elizabeth St Richmond, Vic

For more trial information visit the Members area at the ALLG website

Transition of ALLG trials

Please note the SAE and trial registration fax numbers in the box on the right.

The ALLG is pleased to announce that all trials that were planned to transition from BaCT are now in the ALLG Trial Centre. There is a complete up to date list of trials and CRAs below. You can also visit the website for up to date trial contacts. Thank you for your patience as ALLG Trial Centre staff become familiar with their new (old!) trials. We welcome this change which will ultimately result in an enhanced service for ALLG trials.

TRIAL NO	SHORT TITLE	TRIAL CENTRE	CONTACT
ALL5	Dasatinib in Philadelphia Chromosome-Positive ALL	ALLG Trial Centre	Janey Stone
ALL6	AYA ALL	ALLG Trial Centre	Bereha Khodr
ALL7	RAD001 in relapsed ALL	ALLG Trial Centre	Janey Stone
AMLM12	Idarubicin dose escalation in consolidation therapy in AML	BaCT	Juliana Di Iulio
AMLM15	High dose lenalidomide in adult AML	ALLG Trial Centre	Amanda Jager
AMLM16	Sorafenib in AML	ALLG Trial Centre	Andrew Budniak
AMLM17	High-dose Lenalidomide with epigenetic therapies in relapsed/refractory AML	ALLG Trial Centre	Bala Ravishankar
AMLM18	National Blood Cancer Registry	ALLG Trial Centre	Amanda Jager
BM06	ASCT with RIC in AML	ALLG Trial Centre	Sarah Dewberry
BM07	Zoledronic acid after ASCT	ALLG Trial Centre	Bereha Khodr
CLL5	OFOCIR	BaCT	Juliana Di Iulio
CLL6	Lenalidomide consolidation in CLL with residual disease	ALLG Trial Centre	Andrew Budniak
CML6	TIDEL	ALLG Trial Centre	Bereha Khodr
CML7	Imatinib withdrawal	ALLG Trial Centre	Janey Stone
CML9	TIDELII	ALLG Trial Centre	Bereha Khodr
CML10	RESIST registry	Royal Adelaide	Bronwyn Ortlepp
CML11	Nilotinib and pegylated interferon in CLL	ALLG Trial Centre	Briony Tupper
HD08	RATHL	ALLG Trial Centre	Briony Tupper
HDNHL4	Involved field RT with transplantation for HD and NHL	ALLG Trial Centre	Bereha Khodr
MDS3	5-azacitidine and thalidomide in MDS	ALLG Trial Centre	Ranu Santhosh
MDS4	5-azacitidine and lenalidomide in MDS	ALLG Trial Centre	Ranu Santhosh
MM13	MDex and bortezomib in light-chain (AL) amyloidosis	ALLG Trial Centre	Bereha Khodr
MM14	Pomalidomide in refractory MM	Alfred	Nola Kennedy
MM15	VMP and Melphalan vs VMP and Lenalidomide	Alfred	Nola Kennedy
MM16	Carfilzomib in MM with renal impairment	ALLG Trial Centre	Sarah Dewberry,
MPN01	Myeloplastic Neoplasms Registry	Gosford	Penny Owens
NHL14	Watch and wait	ALLG Trial Centre	Kerina Princi
NHL16	PRIMA	ALLG Trial Centre	Bala Ravishankar
NHL21	Interim PET/CT in poor prognosis DLBCL	ALLG Trial Centre	Briony Tupper
NHL24	Primary CNS NHL	ALLG Trial Centre	Kerina Princi
NHL25	REMARC	ALLG Trial Centre	Bala Ravishankar
NHL27	RELEVANCE	ALLG Trial Centre	Bala Ravishankar
PT1	NCRI Primary thrombocythaemia	ALLG Trial Centre	Janey Stone
AMLM13, AMLM14, APML4, CML8, HD4, LY03, NHL11, NHL13, NHL18, NHL19, NHLLOW4, SC01, SC03		ALLG Trial Centre	Contact Janey Stone

Milestones

- **MM16 LEAD SITE HREC APPROVAL 28/11/2014**
- **BM06 OPENED TO ACCRUAL 5/12/2014, 1ST PATIENT REGISTERED 6/12/2014**
- **CML9 PREPUBLISHED ON-LINE IN *BLOOD* 17/12/2014**

Expressions of Interest

The ALLG Trial Centre is currently calling for Expressions of Interest for trial participation. Please reply to the survey registering your interest before the deadline to be considered.

TRIAL	PI	Contact person	Period for EOI
AMLM20 A programme of development for older patients with AML and high risk MDS	Andrew Wei	Ranu Santhosh	EOI closed (contact Ranu)
CLL7 An Australasian, phase II, multicentre, randomised, study investigating efficacy and safety for dose reduced fludarabine, cyclophosphamide and iv obinutuzumab (G-FC3) vs oral chlorambucil and iv obinutuzumab (G-Clb) in previously untreated, comorbid (CIRS score ≥6), elderly (≥65 years old) patients with CLL	Stephen Mulligan, Xavier Badoux, Con Tam	Kerina Princi	Open
AMLM21 A phase Ib/II clinical evaluation of Ponatinib in combination with 5-azacitidine in patients failing prior therapy for FLT3-ITD positive acute myeloid leukaemia	Andrew Wei	TBA	EOI March/April
NHL29 A Phase II Study of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed DLBCL	Judith Trotman, Emma Verner	TBA	EOI April

Announcements and reminders

Please ensure that all patient documents are fully de-identified. Be mindful of GCP and privacy obligations

Fax coversheets and other documents are being updated to reflect the new contact details for all current transitioned trials.
PLEASE USE THE NEW COVERSHEETS FOR REGISTRATIONS AND SAEs.

New ALLG Trial Centre staff

Kerina Princi, CRA

Kerina Princi (CRA) started in the ALLG Trial Centre in December 2014. She has extensive experience in the health sector, working in clinical and project management roles. Most recently, she managed a clinical trial in oral health which tested a different approach in managing dental decay among adolescent patients. Kerina feels her role as a Clinical Research Associate provides her with a great opportunity to further new skills and knowledge in trial monitoring and build on her broad background.

Ranu Santhosh, CRA

Ranu Santhosh (CRA) started in the ALLG Trial Centre in December 2014. Prior to this she worked as a contractor for Shell and the City of Melbourne. Before moving to Melbourne in August 2013, Ranu worked for about 4 years with Quintiles in India performing roles as CRA and Pharmacovigilance Specialist . With this experience, Ranu will be a valuable asset to our team.

Trials news

Transfer — These trials are **newly transferred** into the ALLG Trial Centre. Please address all correspondence to the new CRA/SCRA listed.

New! — **New trials** are coming on board all the time! This sign means a new concept or the trial is newly opening.

Acute Leukaemia/MDS Disease Group

Acute Leukaemia/MDS Disease Group Chair: Andrew Wei

AMLM18 Registry Transfer
CI: Andrew Wei
CRA: Amanda Jager: ALLG Trial Centre

Amanda is contacting sites to collect documents missing from site files, and will continue this over the coming months. We thank you for your patience and understanding in resolving these discrepancies. **The ALLG is also in the process of opening the AMLM18 registry at another 5 sites.** If you are interested in opening the Registry at your site please contact Amanda.

AMLM16 Transfer
CI: Andrew Wei
CRA: Andrew Budniak ALLG Trial Centre

Please remember to complete the assessments for your patients on time. And please note, the correlative studies in this trial are not optional. The lab studies are pivotal to the success of the trial and for this reason it is essential that all specified samples are collected and dispatched.

AMLM20 A programme of development for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome New!
CI: Andrew Wei
CRA: Ranu Santhosh ALLG Trial Centre

This UK Li-1 trial for elderly AML, led internationally by Cardiff University, is primarily for patients > 60 years with AML or high risk MDS it features the 'pick a winner' style. An initial assessment of novel treatment options leads to an interim analysis. If the preliminary outcome is promising, expansion into a randomised Phase II evaluation stage follows. This design enables several agents to be assessed over the life of the program.

The ALLG is pleased to acknowledge the support partnership with the Leukaemia Foundation Queensland which enables patients to access these novel treatment options.

AMLM21 A phase Ib/II clinical evaluation of Ponatinib in combination with 5-azacitidine in patients failing prior therapy for FLT3-ITD positive acute myeloid leukaemia New!
CI: Andrew Wei

An amended version of the protocol will be reviewed by the SDMC in February. After review at the November Scientific Meeting there is a consensus to remove the single agent azacitidine arm. EOI will be issued in March/April.

AMLM15 Transfer
CI: Andrew Wei
CRA: Amanda Jager ALLG Trial Centre

This pilot study is currently accruing to the last cohort (M5 50 mg lenalidomide) and is expected to close to accrual late February/March. **Before consenting any potential patients, PLEASE CONTACT AMANDA, to ensure a space is available.** Also, please remember to send weekly updates regarding potential DLTs to the CRA during cycles 1 & 2.

Aggressive NHL/HL Disease Group

High grade NHL/HL Disease Group Chair: Mark Hertzberg

NHL29 A Phase II Study of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed DLBCL New!
CI: Judith Trotman, Emma Verner
CRA: TBA, ALLG Trial Centre

With the aging population, DLBCL in the elderly will become more common. Currently R-mini-CHOP chemotherapy is considered a standard treatment for this group of patients. Given the excellent tolerability of Ibrutinib in other lymphoma studies and early data supporting its benefit for the most common subtype of DLBCL, the aim is to improve the survival of elderly patients (over 75) by adding Ibrutinib to R-mini-CHOP.

The ALLG aims to open this trial at two sites in Singapore.

NHL25 REMARC
CI: Judith Trotman
CRA: Bala Ravishankar, ALLG Trial Centre

LYSARC will also be contacting sites for outstanding data needed urgently due to an upcoming interim analysis in April 2015.

All sites also need to immediately upload CT and PET scans, which are also needed urgently for the analysis. Priority for upload are those scans that show patients have progressed. **If your site has not yet set up access to the Imagys upload platform, please nominate a contact person immediately who will be trained by LYSARC.** If difficulties are experienced, there is an option to load scans on CD and mail to LYSARC, but it is not their preferred option. Contact Bala for more information on how to do this.

Please also send histopathology slides to the ALLG Tissue bank as soon as possible. Do not send blocks but arrange for sectioning at your site. Final analysis of this study is planned for September 2016.

Multiple Myeloma Disease Group

Multiple Myeloma Disease Group Chair: Peter Mollee

MM14
CIs: Andrew Spencer, Anna Kalf
CRA: Nola Kennedy, Alfred Clinical Research Centre

This trial is currently open to recruitment and the target is for 80 patients to be randomised. So far 43 patients have been randomised. Given that about 50% of registered patients reach randomisation (at the 4 month mark), it is likely that a total of about 160 patients will need to be registered. With 120 currently registered patients, accruing the number required will take approximately another 4 months.

MM16 Phase II study assessing the effect of carfilzomib treatment on early free light chain kinetics in myeloma patients with renal impairment
CI: Joy Ho, Doug Joshua
CRA: Sarah Dewberry, ALLG Trial Centre

This trial for myeloma patients with renal impairment will investigate the new drug carfilzomib. The aim is to determine early effects on serum free light chain (SFLC) measurements and SFLC correlation with kidney function after 4 months of treatment. The study will also investigate efficacy of the drug and time until progression. Participating sites in this trial are Alfred, Calvary Mater Newcastle, Princess Alexandra, RPA and Royal Adelaide, and the ALLG encourages sites to consider cross referral. Thank you to RPA for submitting the lead site HREC application, which has now been approved.

MM18 Single arm, multicentre study of Carfilzomib in combination with Thalidomide and Dexamethasone (CaTD) in patients with relapsed and/or refractory multiple myeloma (RRMM) New!
CI: Hang Quach

All patients with myeloma are destined to relapse even with the best available approved agents. Median OS from diagnosis is around 5.4 years. Given this remains an incurable disease, future improved OS is therefore reliant on the expansion of salvage options.

The new drug Carfilzomib is a second-generation proteasome inhibitor and is structurally and mechanistically different to bortezomib. As monotherapy, carfizomib has demonstrated robust and durable activity in heavily pretreated patients in phase I and II trials.

The primary objective of this new study is to assess combination carfilzomib, thalidomide and dexamethasone (CaTD) in relapsed / refractory MM patients with 1 to 3 prior lines of therapies. The regimen is potentially an affordable regimen that will be applicable to the Asia-Pacific region. There will also be correlative studies.

This study may include a collaboration with the International Myeloma Foundation and its affiliate the Asian Myeloma Network.

The accrual period will be 2 years, with treatment duration approximately 18 months and 2 years follow up. The total accrual target is 100 (50 ALLG, 50 AMN) .

Supportive Care Disease Group

Supportive Care Disease Group Chair: Con Tam

FUTuRE Fertility Study New!
Antoinette Anazodo

The ALLG is pleased to endorse the Australasian Oncofertility Registry, an observational registry recording details of fertility preservation and reproductive potential for patients with cancer.

The Registry will capture data on children, adolescents, young adults and adults under four themes: communication and referral about fertility preservation; uptake of fertility preservation; fertility potential after diagnosis; and natural and assisted pregnancies. With ALLG support, Information on haematology patients will be provided annually.

Currently oncofertility guidelines have limited evidence based recommendations. Research outcomes will be used to develop evidence-based national guidelines. Ongoing collaboration will also provide further opportunities to bridge the gap in effectively communicating fertility preservation options and strategies to patients at the time of diagnosis and before starting treatment. For further information contact the FUTuRE study at info@futurefertility.com.au

CML/Myeloproliferative Disease Group

CML/MPN Disease Group Chairs: Con Tam, Tim Hughes

CML11
CIs: David Yeung, Tim Hughes, Andrew Grigg.
CRA: Briony Tupper, ALLG Trial Centre

The ALLG Trial Centre is seeking additional sites to participate in this trial. If your site is interested please contact Briony. The eCRFs are still in development and expected to be implemented later this year.

CML9 TIDELII Transfer
CIs: Tim Hughes, Andrew Grigg
Project consultant : Bereha Khodr, ALLG Trial Centre

This study, which was designed to optimise outcomes for newly-diagnosed CML, was pre-published on-line in Blood 17/12/2014 (DT Yeung et al). The study showed that upfront imatinib treatment in CML with selective nilotinib switching led to high rates of OS, TFS, EMR and MMR. The authors conclude that their strategy may be preferable to universal upfront use of 2nd generation TKIs based on efficacy and toxicity as well as economic concerns. **Congratulations to the PIs and also thank you to all participating sites.** Plans for ongoing data collection and follow up are currently under discussion.

MPN01 Myeloplastic Neoplasms Registry
CIs: Cecily Forsyth, Andrew Grigg, David Ross, Wendy Erber
CRA: Penny Owens , Gosford Hospital

This Registry is currently accruing patients at 18 sites in Australia and NZ, and plans to expand to more sites this year. The data is entered on-line, with instructions in the Study Coordinators' Manual available to download from the ALLG website. There are also correlative studies and tissue banking of samples.

Low grade NHL/CLL Disease Group

NHL/CLL Disease Group Chairs Stephen Mulligan, Campbell Tiley

CLL7 An Australasian, phase II, multicentre, randomised, study investigating efficacy and safety for dose reduced oral fludarabine, oral cyclophosphamide and i.v. obinutuzumab (poFCivG) versus oral chlorambucil and i.v. obinutuzumab in previously untreated, comorbid (CIRS score ≥6), elderly (≥65 years old) patients with chronic lymphocytic leukaemia (CLL) New!
CIs: Stephen Mulligan, Xavier Badoux, Con Tam
CRA: Kerina Princi, ALLG Trial Centre

It's now all systems go with this trial aimed at the elderly patient with comorbidities. The trial will redefine the treatment paradigm for those disadvantaged by age and disease. Patients are randomised to : (1) Fludarabine, cyclophosphamide and novel agent GA101 or (2) chlorambucil (Cbl) and GA101. The aim is to determine whether G-FC is tolerable and more effective than G-Cbl in this patient group. The trial incorporates substantial laboratory correlative studies and a suite of QOL and frailty measures.

Expressions of interest are currently under way, with 15-20 sites expected to participate. The protocol has been submitted to HREC at Royal North Shore and St George. Thank you to St George for acting as lead site. Additional sites will be added to the lead site approval as they indicate their interest.

Unfortunately the NHMRC/PdCCR scheme application submitted in 2014 was not successful. An application for a NHMRC Project Grant is being considered for 2015.

NHL16 PRIMA Transfer
CI: John Seymour
CRA: Bala Ravishankar, ALLG Trial Centre.

Documents for the amendment extending follow-up until December 2016 have been sent to all 30 participating sites. Of these, 16 have already obtained approval, 8 are still in process. Whether the remaining 4 sites will participate is still being determined.

BMT Disease Group

BMT Disease Group Chair Ian Lewis

BM06
CI: David Ritchie
CRA: Sarah Dewberry, ALLG Trial Centre

This important Swedish based trial will provide an evidence base for bone marrow transplant. There will be five sites in Australia/NZ. The first patient was accrued at RMH on 5/12/2014 and Royal Adelaide were activated on 4/12/2014. Christchurch has opened the trial independently but will transfer to ALLG sponsorship in due course. Wellington will also participate under ALLG sponsorship.

This newsletter was edited by Janey Stone and approved by Delaine Smith and Megan Sanders.

Questions or comments? E-mail us at info@allg.org.au